Table 3 Description of treatment outcome of patients who received cytotoxic chemotherapy and/or targeted agents as desmoid treatment
Sex | Site DT | Age (years) | Treatment | Effect on desmoid growth | Follow-up (months) |
|---|---|---|---|---|---|
Male | Mesentery | 45 | Irresectable DT, etoposide and ifosfamide, tamoxifen tamoxifen and LHRH-agonist anastrozole | Quick regression DT, necrosis in DT Stabilisation, after 5 years progression Progression | 5 70 5 |
Male | Head, abd. wall and mesentery | 15–17 | R2 resection DT head, RT mes. DT, sulindac, toremifene doxorubicine and DTIC, R2 resection mes. DT sulindac, toremifene, R2 resection abd. wall DT all medication stopped | Progression mes. DT Stabilisation, after 2 years abd. wall DT Both periods of progression and regression, after 2 years growth DT head, DT mes. and abd. wall stable Stabilisation | 35 38 100 36 |
Male | Mesentery | 29 | R2 resection, sulindac, toremifene doxorubicine and carboplatin R2 resection, sulindac, tamoxifen | Progression Regression <25% Stabilisation | 11 7 50 |
Male | Mesentery | 29 | R2 resection, sulindac, tamoxifen, toremifene doxorubicine and ifosfamide, sulindac, toremifene imatinib | Progression Stabilisation, after 8 months progression Stabilisation, but fistulas and abscesses at DT | 38 8 10 |
Female | Abd. wall, trunk, breasts, neck | 25–40 | Multiple R2 resections, tamoxifen, sulindac, LHRH-agonists, anastrozole, radiotherapy imatinib | Progression and multiple new DT Progression Progression | 11 10 |
Male | Mesentery | 32 | R2 resection doxorubicine and DTIC | Progression | 19 |
| Â | Â | Â | Â | Regression, death not due to DT | 184 |
Male | Mesentery | 30 | Chemotherapya and radiotherapy, R2 resection colchicine, LHRH-agonists, anti-estrogens, prednison, IFN | Stabilisation for 4 years Progression; after colchicine multiple abscesses; death due to DT | 51 58 |
Female | Mesentery and abd. wall | 24 | Naproxen, toremifene doxorubicine and DTIC | Progression Progression, death due to DT | 16 3 |
Female | Mesentery | 33–35 | Sulindac, anti-estrogens, DT irresectable liposomal doxorubicine | Progression Death pulmonary embolism, due to compression of DT on the large veins | 24 0 |
Female | Mesentery | 35–37 | Wait-and-see, sulindac, celecoxib, tamoxifen, toremifene carboplatin and doxorubicine imatinib fulvestrant | Progression Necrosis in DT, fistulas and abscesses Stabilisation, after 1 year progression Stabilisation, after 2 years progression and death due to DT | 37 7 12 19 |
Male | Mesentery | 47 | Irresectable DT, sulindac, tamoxifen vinblastin and methotrexat | Progression Progression, death due to desmoid | 4 18 |
